Suicidal Ideation Research Dashboard
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 90 studies associated with Suicidal Ideation.
Here is a small sampling of Suicidal Ideation studies by title:
- The role of depression in the relationship between cannabis use and suicidal behaviours: A systematic review and meta-analysis
- Association of substance use with suicide mortality: An updated systematic review and meta-analysis
- National Trends in Suicidal Thoughts and Suicide Attempts Among High School Students in the United States
- Cannabis use and suicide in people with a diagnosis of schizophrenia: a systematic review and meta-analysis of longitudinal, case control, and cross-sectional studies
- Psychosis and suicide attempt following a single use of delta-9-tetrahydrocannabiphorol: A case report
Components of the Suicidal Ideation Research Dashboard
- Dosing information available for Suicidal Ideation
- Chemotype guidance for treating Suicidal Ideation with cannabis
- Synopsis of cannabis research for Suicidal Ideation
- Individual study details for Suicidal Ideation
Ready to become a subscriber? Go to our PRICING page.
Suicidal Ideation Research Dashboard
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 90 studies associated with Suicidal Ideation.
Here is a small sampling of Suicidal Ideation studies by title:
- The role of depression in the relationship between cannabis use and suicidal behaviours: A systematic review and meta-analysis
- Association of substance use with suicide mortality: An updated systematic review and meta-analysis
- National Trends in Suicidal Thoughts and Suicide Attempts Among High School Students in the United States
- Cannabis use and suicide in people with a diagnosis of schizophrenia: a systematic review and meta-analysis of longitudinal, case control, and cross-sectional studies
- Psychosis and suicide attempt following a single use of delta-9-tetrahydrocannabiphorol: A case report
Components of the Suicidal Ideation Research Dashboard
- Dosing information available for Suicidal Ideation
- Chemotype guidance for treating Suicidal Ideation with cannabis
- Synopsis of cannabis research for Suicidal Ideation
- Individual study details for Suicidal Ideation
Ready to become a subscriber? Go to our PRICING page.
Select New Condition
Overview - Suicidal Ideation
Description of Suicidal Ideation
Suicide and Suicidal Ideation: A Biopsychosocial Perspective
While the motivations behind suicide attempts are profoundly personal and varied, they are rarely caused by psychological distress alone. As early as 1897, French sociologist Émile Durkheim, in his seminal work Le Suicide, argued that suicide is often rooted in social disconnection. He found that individuals who lack a sense of belonging, integration, and meaningful relationships—whether through family, community, religion, or society at large—are at significantly higher risk for suicidal thoughts and behaviors.
Durkheim’s insight remains relevant: social cohesion is a protective factor against self-harm. For example, data from 2001–2007 shows that nearly one in five U.S. veterans who died during that period took their own lives—21.3% among those deployed and 19.7% among those not deployed—highlighting the lasting impact of trauma, alienation, and inadequate reintegration support.
In modern psychiatric frameworks, suicidal ideation—persistent thoughts about ending one’s life—is primarily linked to mental health conditions such as depression, anxiety, PTSD, or bipolar disorder, and is typically treated with psychopharmaceuticals. However, this biomedical model often overlooks societal contributors like poverty, discrimination, racial disparities, loneliness, and existential despair. A more integrative approach considers the biopsychosocial dimensions of suicide—where biology, psychology, and social context intersect—and recognizes that healing must address both internal suffering and the external conditions that sustain it.
Disease Classification
Condition: Suicidal IdeationDisease Family:
Organ System: Mental/Emotional System
ICD-10 Chapter: Injury, Poisoning and Certain Other Consequences of External Causes
ICD-10 Code: T14.91
Suicidal Ideation Symptoms:
Symptoms are typically reflective of severe major depressive disorder (SIGECAPS), moodswings, an underlying mental condition such as anxiety (PTSD), depression, psychosis, for example; expressions of hopelessness, planning or getting the means to commit suicide, expressing the wish to commit suicide, alienation, lack of meaningful connections, desire to punish others with self-harm.Also known as:
Attempted SuicideDrug Interactions
THC Interaction with Pharmaceutical Drugs
- Tetrahydrocannabinol (THC) can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol.
- THC is metabolized by an inhibitor of several enzymatic liver pathways referred to as cytochrome P450 (aka CYP450). There are more than 50 enzymes belonging to this enzyme family, several of which are responsible for the breakdown of common drugs such as antidepressants (e.g., amitriptyline, doxepin, fluvoxamine), antipsychotics (haloperidol, clozapine, Stelazine), beta-blockers (e.g., propranolol), bronchodilators (e.g., theophylline), or blood thinners (e.g., warfarin). Thus, patients taking these medication classes may find that THC increases the concentration and effects of these drugs and the impact duration.
- Clinical observation (not yet confirmed by clinical trials) suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.
If you are interested in the interaction potential of specific pharmaceuticals with THC, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.
CBD Interaction with Pharmaceutical Drugs
- Cannabidiol (CBD) may alter the action of metabolic enzymes (specific drug-transport mechanisms) and alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects.
- Groups of drugs affected include anti-epileptics, psychiatric drugs, and drugs affecting metabolic enzymes.
- Clinical observations (not yet confirmed by clinical trials) suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD.
If you are interested in the interaction potential of specific pharmaceuticals with CBD, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.
THC/CBD Interaction with Pharmaceutical Drugs
In general, when using cannabinoid-based therapeutics that contain both THC and CBD consider the ratio between them and weigh the relevant information displayed in the individual THC and CBD Drug Interaction windows accordingly.
If you are interested in the interaction potential of specific pharmaceuticals with both primary cannabinoids and THC/CBD, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.
Concerns about Cannabis and Cancer-related Immunotherapies:
Some recent clinical observational studies have suggested that the co-administration of cannabinoid-based therapeutics and immunotherapy or immune checkpoint inhibitors in the treatment of certain types of cancer has been associated with worse overall survival rates (T. Taha et al., 2019; A. Biedny et al., 2020; G. Bar-Sela et al., 2020).
However, other studies have suggested that the co-commitment use of immune checkpoint inhibitors and cannabis-induced no such deleterious effects. More specifically, one trial was conducted on animals resulting in data suggesting that cannabis did not negatively affect the properties of immune checkpoint inhibitors (B. Waissengrin et al., 2023). The same authors compared the previous study results with findings from a cohort of 201 patients with metastatic non-small cell lung cancer who received treatment with monotherapy pembrolizumab as a first-line treatment and adjunct cannabis to treat mainly pain and loss of appetite. Their time to tumor progression was 6.1 versus 5.6 months, and overall survival differed between 54.9 versus 23.6 months in cannabis-naïve patients and cannabis-using patients, respectively. However, while numerically different, the authors write that these differences were not statistically significant, leading them to suggest that “These data provide reassurance regarding the absence of a deleterious effect of cannabis in this clinical setting.”
Dosing Considerations
THC Dosage Considerations
- THC micro dose: 0.1 mg to 0.4 mg
- THC low dose: 0.5 mg to 5 mg
- THC medium dose: 6 mg to 20 mg
- THC high dose: 21 mg to 50+ mg
CBD Dosage Considerations
- CBD low dose: 0.4 mg to 19 mg
- CBD medium dose: 20 mg to 99 mg
- CBD high dose: 100 mg to 800+ mg (upper limits tested ~1,500mg)
Disclaimer
Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own licensed physician or other medical professional. You
should not use the information contained herein for diagnosing or treating a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a
medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.
